Clinical trials: Neoplasms, Germ Cell and Embryonal
Merkel Cell Carcinoma, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
This phase I trial studies the side effects and how well nivolumab works when given together with radiation therapy or ipilimumab as adjuvant therapy in treating patients with Merkel cell cancer.
- Conditions
- Merkel Cell Carcinoma, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT03798639
- Testing
- Ipilimumab, Nivolumab, Radiation Therapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Claire Verschraegen
Solid Tumors
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT03634982
- Testing
- RMC-4630
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Revolution Medicines, Inc.
Melanoma
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
The purpose of the study is to assess the safety and efficacy of BGB324 given together with standard treatment, pembrolizumab or dabrafenib and trametinib, compared to standard treatment alone,
- Trial name
- NCT02872259
- Testing
- BGB324+pembrolizumab, BGB324+dabrafenib and trametinib, pembrolizumab
- Where
- 5 sites in Norway
- Volunteers
- 74 people
- Sponsor
- Haukeland University Hospital
Glioma
Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas
This substudy will investigate a new imaging approach using positron emission tomography (PET) and two investigational drugs ([18F]FET and [18F]FMISO) to see if the imaging results will help with the placement of catheters for…
- Trial name
- NCT07778979
- Testing
- [18F]FMISO-PET with contrast-enhanced MRI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Glioma, Malignant, IDH Mutation
Window of Opportunity Study of DSP-0390 in Gliomas
This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant glioma undergoing tumor resection. Tissue will be collected during surgical resection.
- Trial name
- NCT06636162
- Testing
- DSP-0390
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy in treating patients who have…
- Trial name
- NCT00002786
- Testing
- aldesleukin, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Neuroendocrine Tumours
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
To evaluate, in patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy at the moment of study inclusion, the efficacy of lanreotide Autogel in tumour growth…
- Trial name
- NCT00326469
- Testing
- lanreotide (Autogel formulation)
- Where
- 27 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Ipsen
Melanoma Stage III or IV
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have…
- Trial name
- NCT00243594
- Testing
- Peptide-pulsed dendritic cells
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Immunotherapy
Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones
Most of HLA-A2 melanomas express Melan-A/MART-1 antigen and are recognized by tumor reactive Melan-A specific T lymphocytes. By using blood samples from HLA-A2 melanoma patients (stage III and IV), our goal is to produce a tumor…
- Trial name
- NCT00720031
- Testing
- autologous Melan-A/MART-1 specific CTL clones
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Nantes University Hospital
Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Study of Tumor Samples From Patients With Ewing Sarcoma
This laboratory study is looking at tumor samples from patients with Ewing sarcoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and…
- Trial name
- NCT00898053
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Children's Oncology Group
Glioblastoma, Recurrent Glioblastoma
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
This phase I trial studies the side effects and best dose of adavosertib when given together with radiation therapy and temozolomide in treating patients with glioblastoma that is newly diagnosed or has come back.
- Trial name
- NCT01849146
- Testing
- Adavosertib, Radiation Therapy, Temozolomide
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma.
The purpose of this pilot study is to evaluate digitally supported skin self-examination compared to usual care in people treated for localised melanoma.
- Trial name
- MEL-SELF (NCT03581188)
- Testing
- Patient-led surveillance, Clinician-led surveillance
- Where
- 3 sites in Australia
- Volunteers
- 100 people
- Sponsor
- University of Sydney
Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases…
- Trial name
- HAITILS (NCT04812470)
- Testing
- Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Vastra Gotaland Region
Melanoma
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.
- Trial name
- NCT02155322
- Testing
- Pegylated Interferon Alfa-2b
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Skin Cancer
DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer
The purpose of this study is to evaluate the clinical validity of the proprietary DermaSensor Elastic Scattering Spectroscopy (ESS) device and classifier algorithm to support assessment of skin lesions suggestive of melanoma…
- Trial name
- DERM-SUCCESS (NCT06690086)
- Testing
- Lesion biopsy, DermaSensor Device Use
- Where
- United States
- Volunteers
- 1,028 people
- Sponsor
- DermaSensor, Inc.
Neuroendocrine Tumors
Biomarker Identification of Radionuclide Therapy-induced Radiation Responses
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-[Tyr3]octreotate (177Lu-DOTATATE) is a form of internal radiation treatment for patients with neuroendocrine tumors (NET) to reduce tumor growth and stabilize…
- Trial name
- Radio-Marker (NCT05513469)
- Testing
- Lutathera
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Erasmus Medical Center
Malignant Head and Neck Neoplasm, Malignant Neoplasm
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and…
- Conditions
- Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix
- Trial name
- NCT01365169
- Testing
- Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, Medulloblastoma
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses.
- Conditions
- Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Trial name
- NCT04049669
- Testing
- Indoximod, Partial Radiation, Full-dose Radiation
- Where
- 5 sites in United States
- Volunteers
- 130 people
- Sponsor
- Theodore S. Johnson
Malignant Glioma, Neoplasms
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
This human Phase 1 trial is a continuation of a Phase 1 trial which enrolled patients with recurrent gliomas (#TJU-14379-101) and which was designed after a previously conducted Phase 1 human trial at our institution.
- Trial name
- NCT02507583
- Testing
- IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- david andrews
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected).
- Trial name
- NCT03655756
- Testing
- IFx-Hu2.0
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- TuHURA Biosciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.